Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › BGM0504 phase 3 (obesity)

BGM0504 phase 3 (obesity)

BGM0504 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
BGM0504
Population
obesity
Phase
3
Duration
52 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
BGM0504 15 mgobesity china52——−19.2 % vs −3.1 %
Δ −16.1 pp
—0.7—————verified
BGM0504 10 mgobesity china52——−17.3 % vs −3.1 %
Δ −14.2 pp
—1.2—————verified
BGM0504 5 mgobesity china52——−14.3 % vs −3.1 %
Δ −11.2 pp
—1.7—————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (6)
  • BGM0504 15 mg · weight_tp · Results
    15 mg: −19.19% (95% CI: −20.63 to −17.76), corresponding to −18.26 kg (95% CI: −19.66 to −16.86)
  • BGM0504 15 mg · ae_dc · HKEX filing
    BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
  • BGM0504 10 mg · weight_tp · Results
    10 mg: −17.27% (95% CI: −18.67 to −15.88), corresponding to −16.47 kg (95% CI: −17.85 to −15.09)
  • BGM0504 10 mg · ae_dc · HKEX filing
    BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
  • BGM0504 5 mg · weight_tp · Results
    5 mg: −14.31% (95% CI: −15.69 to −12.93), corresponding to −13.48 kg (95% CI: −14.83 to −12.13)
  • BGM0504 5 mg · ae_dc · HKEX filing
    BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: BGM0504 phase 3 (obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/bgm0504-phase-3/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.